¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Diascan Abnormal/High Control InVt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • safety control
    ¾ÈÀü°ü¸®
  • self-control disorder
    ÀÚ±âÁ¶ÀýÀå¾Ö
  • sensitivity control
    °¨µµÁ¶Á¤±â, °¨µµÁ¶Àý
  • sibling control
    ÇüÁ¦´ëÁ¶±º
  • venereal disease control
    ¼ºº´°ü¸®
  • vestibuloequilibratory control
    ¾È¶ãÆòÇü±â´ÉÁ¶Àý, ÀüÁ¤ÆòÇü±â´ÉÁ¶Àý
  • voice-activated control
    À½¼ºÀÛµ¿Á¶Àý
  • volitional control
    ÀÇÁöÀûÅëÁ¦
  • weight control program
    üÁßÁ¶Àý°èȹ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • tonic control
    °­Á÷Á¦¾î, ±äÀåÁ¶Àý
  • tumor control
    Á¾¾ç¾ïÁ¦
  • venereal disease control
    ¼ºº´°ü¸®
  • vestibuloequilibratory control
    ¾È¶ãÆòÇü±â´ÉÁ¶Àý
  • voice-activated control
    À½¼ºÀÛµ¿Á¶Àý
  • volitional control
    ÀÚ¹ßÀûÅëÁ¦
  • water pollution control
    ¼öÁú¿À¿°°ü¸®
  • water quality control
    ¼öÁú°ü¸®
  • impulse control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö, Ãæµ¿Á¶Àýº´
  • self-control disorder
    ÀÚ±âÁ¶ÀýÀå¾Ö
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡
  • gate-control theory
    ¹®Á¶ÀýÀÌ·Ð
  • head control
    ¸Ó¸®°¡´©±â
  • infection control study
    °¨¿°°ü¸®Á¶»ç
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • high risk infant
    °íÀ§Ç輺 ¿µ¾Æ.
  • high sagittal presentation
    °íÀ§Á¾Á¤À§(ÍÔêÈðýïÒêÈ).
  • high signal
    °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£ °­µµ
  • high spatial frequency algorithm
    °í °ø°£ Á֯ļö ¿¬»ê
  • high speed
    °í¼ÓÀÇ
  • high speed core cut biopsy
    °í¼Ó Á᫐ »ý°Ë
  • high spinal anesthesia
    °íÀ§Ã´Ã߸¶Ãë(¹ý).
  • high temperature sterlization
    °í¿Â¸ê±Õ.
  • high tension pulse
    °í¾Ð¸Æ(ÍÔäâØæ), °íÀ可(ÍÔí娿).
  • high tone deafness
    °íÀ½¼º³­Ã»
  • high tracheostomy
    »ó±â°üÀý°³¼ú
  • high vacuum
    °íÁø°ø(°íÁø°ø).
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • pseudodiastole in high intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿¿¡¼­ À§À̿ϱâ
  • recombination, high frequency (Hfr)
    °íºóµµÀçÁ¶ÇÕ
  • super high field MR scanner
    ÃʰíÀÚÀå MR ½ºÄ³³Ê, ÃʰíÀÚÀå ÀÚ±â°ø¸í?
  • tolerance to high altitude
    °í¼Ò³»¼º(ÍÔá¶Ò±àõ).
  • tracheostomy, high
    »ó±â°üÀý°³¼ú
  • transduction, high frequency
    °íºóµµÇüÁúµµÀÔ
  • ultra high field MR scanner
    ÃʰíÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • accuracy control
    Á¤È®¼º Á¶Àý
  • admission by legal control
    Á¶Ä¡ÀÔ¿ø.
  • air pollution control
    ´ë±â¿À¿°¹æÁö<±ÔÁ¦> (ÊÙËÑ̤<˻̡>).
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý.
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤(ÊÙÌ¡Ì¡Ë§Ëø).
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤(¡­ð²ð¥ËþïÒ).
  • biologics control laboratory
    [º´¸®,¹Ì»ý,±â»ý,¸é¿ª,¹ÙÀÌ,¿¹¹æ]»ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò(Ë×ËÑ̡̡˴ËöËàÌ´ËÛ).
  • biologics control laboratory
    º´¸®,¹Ì»ý,±â»ý,¸é¿ª,¹ÙÀÌ,¿¹¹æ»ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò(ßæÚªð²ð¥Î·ìµãËúÐá¶).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
ALFT abnormal liver function test
ALIP abnormal localized immature mye-loid precursor
AMPS abnormal mucopolysacchariduria; acid mucopolysaccharide
APV abnormal posterior vector
ASP abnormal spinal posture; acute symmetric polyarthritis; African swine pox; aged substrate plasma; al...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
DCR Dominant Control Region
ECA Electrical control activity
HACCP Hazard Analysis Critical Control Point
HACCP Hazard Analysis and Critical Control Point
HLC Health Locus of Control
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
high convex The segment of a sphere of short radius.
(05 Mar 2000)
high density lipoprotein <biochemistry> These lipoproteins acts to carry cholesterol in the bloodstream.
Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease).
Recent studies show a low high density lipoprotein level is the strongest predictor of cardiovascular death in women.
Acronym: HDL
(18 Nov 1997)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
high-egg-passage vaccine Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats.
(05 Mar 2000)
high endothelial postcapillary venules Venule's in the lymph nodes, tonsils, and Peyer's patches that have a high-walled endothelium through which blood lymphocytes migrate into the lymphatic parenchyma.
(05 Mar 2000)
high enema An enema instilled high up into the colon.
Synonym: enteroclysis.
(05 Mar 2000)
high energy bond <chemistry> Chemical bonds that release more than 25kJ/mol on hydrolysis: their importance is that the energy can be used to transfer the hydrolysed residue to another compound. The risk in using the term is that students may think the bond itself is different in some way, whereas it is the compound that matters. Hydrolysis of creatine phosphate yields 42.7kJ/mol, of phosphoenolpyruvate, 53.2, ATP to ADP, 30.5: the latter is important because it shows that energetically the hydrolysis of creatine phosphate will suffice to reconstitute ATP, hence the use of creatine phosphate in muscle.
(18 Nov 1997)
high energy compounds Classically, a group of phosphoric esters whose hydrolysis takes place with a standard free energy change of -5 to -15 kcal/mol (or, -20 to -63 kJ/mol) (in contrast to -1 to -4 kcal/mol or, -4 to -17 kJ/mol) for simple phosphoric esters like glucose-6-phosphate or alpha-glycerophosphates), thus being capable of driving energy-consuming reactions in living cells or reconstituted cell-free systems; adenosine 5'-triphosphate, with respect to the beta-and gamma-phosphates, is the best known and is regarded as the immediate energy source for most metabolic syntheses. The general types are acid anhydrides, phosphoric esters of enols, phosphamic acid (R-NH-PO3H2) derivatives, acyl thioesters (e.g., of coenzyme A), sulfonium compound's (R3-S+), and aminoacyl esters of ribosyl moieties.
See: high energy phosphates.
(05 Mar 2000)
high energy particle generating unit A machine capable of providing highly energised radiation for the purposes of radiotherapy treatment.
(16 Dec 1997)
high energy phosphate bond See: high energy phosphates.
(05 Mar 2000)
high energy phosphates Those phosphate's that, on hydrolysis, yield an unusually large amount of energy; e.g., nucleotide polyphosphates such as ATP, enol phosphate's such as phosphoenolpyruvate.
See: high energy compounds.
Synonym: energy-rich phosphates.
(05 Mar 2000)
high-energy shock waves Compression waves of large amplitude, across which density, pressure, and particle velocity change drastically.
(12 Dec 1998)
high extinction microscopy <technique> Polarized-light, interference, fluorescence, and other modes of microscopy using polarization rectifiers and other devices to achieve a high degree of back- ground extinction in order to bring out the signal originating from a very small degree of birefringence, optical path difference, fluorescence etc.
(05 Aug 1998)
high-fat diet A diet containing large amounts of fat.
(05 Mar 2000)
high-fibre diet A diet high in the nondigestible part of plants, which is fibre. Fibre is found in fruits, vegetables, whole grains, and legumes. Insoluble fibre increases stool bulk, decreases transit time of food in the bowel, and decreases constipation and the risk of colon cancer. Soluble fibre delays absorption of glucose, which helps to control blood sugar in diabetes mellitus, and delays absorption of lipids, which helps to control hyperlipidemia. Recommended in treatment of diverticular disease of the colon.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • high horse
    (¿¾³¯ ±ÍÀÎÀÌ Å° Å« ¸»À» ź µ¥¼­)°Å¸¸;¿À¸¸(ÇÑ Åµµ);¾ð¨À½
  • high jinks
    ½Å³ª°Ô(Èïû¸Áû) ¶°µé±â
  • high jump
    ³ôÀ̶ٱâ
  • high life
    »ó·ù »çȸ(ÀÇ »ýȰ)
  • high liver
    »çÄ¡½º·¯¿î »ýȰÀ» ÇÏ´Â »ç¶÷;¹Ì½Ä°¡
  • high living
    ȣȭ½º·¯¿î »ýȰ 
  • high noon
    Çѳ·;Á¤¿À
  • high pillow
    °Å¹°;Áß¿ä Àι°
  • high pitch
    (³ëÁ¡ »óÀÎÀÇ)ÆÇ¸Å´ë
  • high place
    »ê²À´ë±âÀÇ ¿¹¹è Àå¼Ò;Áß¿äÇÑ ÁöÀ§;¿äÁ÷;°í°ü
  • high pockets
    Ű´Ù¸®
  • high point
    Áß´ëÇÑ ½ÃÁ¡;ÃÖ°íÀÇ ½Ã±â
  • high polymer
    °íºÐÀÚ(°Å´ëºÐÀÚ) ¹°Áú
  • high polymer chemistry
    °íºÐÀÚ(È­)ÇÐÀÇ;°­·ÂÇÑ;(±¤ÇÐ ±â±â°¡)¹èÀ²ÀÌ ³ôÀº;Á¤·ÂÀûÀÎ
  • high priest
    Á¦»çÀå;(¿¾ À¯´ë±³ÀÇ)´ëÁ¦»çÀå;°í½Â;(ÁÖÀÇ,¿îµ¿ÀÇ)ÁöµµÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á